Introduction
Osteoarthritis (OA) has long been considered the unique consequence of a wear and tear process leading to cartilage degradation. Indeed, it is true that excessive mechanical stress on any joint leads to cartilage loss, with the production of osteophytes thought to be a reactive process of the bone to protect and stabilize the altered joint (1) . This initial paradigm has been slowly but deeply modified in the past 20 years due to critical discoveries (2) . First, the enzymes involved in cartilage degradation were identified as belonging to the metalloproteinase and ADAMTS families, with proinflammatory cytokines regulating all of these enzymes. It was the first time that the pathophysiology of OA was associated with a role of soluble mediators better known in the pathophysiology of many other classic inflammatory diseases. Second, whereas synovitis was considered to be pathognomonic of rheumatoid arthritis, some groups demonstrated that a mild to severe synovitis reaction was frequently present in OA and that its intensity was correlated with prognosis (3, 4) . Third, understanding of the role of obesity in OA shifted from the perception that it had an exclusive deleterious mechanical effect on load-bearing joints to a recognition of its capacity to play a role in hand OA also. Indeed, epidemiologic studies demonstrated that obese patients have a 2-fold increase in the rate of hand OA compared to a nonobese population (5) .
These unexpected results have been interpreted as being related to a well-known systemic release of proinflammatory cytokines primarily by abdominal adipose tissue (called adipocytokines or adipokines), which cause a low-grade inflammatory state involved in damage to many peripheral tissues, including joint tissues (2) . More recently, the intraarticular fat pads, adipose tissue present inside some joints, have been considered to be a new potential source of adipokines (6) . All of this evidence of the role of inflammation in OA opened the door to a novel and exciting area of research on the molecular interactions between local articular tissues/cells and distant organs/tissues and how these metabolic processes are disturbed in OA.
Epidemiologic and prospective clinical studies linking metabolic syndrome and OA Puenpatom and Victor (7) were the first to suggest that, in addition to obesity, the metabolic syndrome, defined as the association of components that independently increase the risk of cardiovascular events (abdominal adiposity, diabetes mellitus [DM] or insulin resistance, high cholesterol, and high blood pressure), could be an independent risk factor for OA. They found that 59% of OA patients had metabolic syndrome compared to 23% of the general population in the Third National Health and Nutrition Examination Survey cohort. Furthermore, they calculated that having OA at 44 years old increases the risk of having concomitant metabolic syndrome by 5.26-fold, suggesting that the presence of knee OA should inform the practitioner of a need to screen for metabolic syndrome. Other cross-sectional studies confirmed the association between metabolic 
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BERENBAUM ET AL syndrome and OA (8) (9) (10) (11) (12) , even though obesity was sometimes a strong confounding factor longitudinally (13) . The presence of metabolic syndrome is also associated with hand OA. Taking advantage of an increased prevalence of metabolic syndrome in HIV patients, Tomi et al (14) looked at the prevalence of hand OA in sex-and age-matched HIV patients according to their metabolic status. Interestingly, hand OA prevalence was higher for those with metabolic syndrome than for those without it (64.7% versus 46.3%; P 5 0.002), and the severity of hand OA was greater in those with metabolic syndrome (14 (16) .
Interestingly, some of these studies showed that incidence and severity were positively correlated with the number of cardiometabolic parameters. In a multivariate analysis based on a cohort of 1,384 Japanese individuals followed up for 3 years (the ROAD cohort), the incidence of knee OA significantly increased according to the number of metabolic syndrome components (OR 2.33 for 1 versus 0 components, 2.82 for 2 versus 0 components, and 9.83 for $3 versus 0 components) (17) . Similarly, progression of knee OA significantly increased according to the number of components present (OR 1.38 for 1 versus 0 components, 2.29 for 2 versus 0 components, and 2.80 for $3 versus 0 components). In a large Australian population cohort followed up during 2003-2007 (the Melbourne Collaborative Cohort Study), 660 patients had a total knee replacement (TKR) for OA (18 However, the weight of each of these factors for increasing OA risk remains largely unknown. DM is associated with an independent increase in incident, prevalent, and severe OA, although discrepancies exist in the literature (ref. 19 ; for review, see ref. 22) . Recent studies have shown an increased risk of knee or hand OA in patients with hypertension and/or atherosclerosis, supporting the hypothesis that an abnormal perfusion of the subchondral bone due to atherosclerosis could participate in the OA process (18, 21, 23) . Interestingly, this hypothesis fits with a recent study showing an association of serum cholesterol and triglyceride levels with the incidence of bone marrow lesions on knee magnetic resonance imaging (MRI) at 2 years in a population of asymptomatic middle-aged women (20 (24) . Such an independent association has also been shown in hand OA (25) .
Some groups looked at the prognostic value of plasma concentration of adipokines in OA cohorts. An association between leptin levels (but not adiponectin levels) and knee OA occurrence and progression was demonstrated in a 5-year cohort, but this association disappeared after adjustment for BMI (26) . In the Cohort Hip and Cohort Knee (CHECK), there was a weak association between resistin levels (but not leptin levels) and disease progression (27) . Finally, hand OA patients with elevated adiponectin levels (but not elevated leptin or resistin levels) had decreased disease progression compared to those with normal or low levels in a Dutch cohort (28) .
Taken together, these epidemiologic studies show clear associations between OA, the metabolic syndrome, and its components, with some of them being clearly independent of the overload effect of obesity ( Figure 1 ). However, there is high heterogeneity in the design of all of these cross-sectional and longitudinal epidemiologic studies (definition of the metabolic syndrome, sex selection, record of medication, etc.), which prevents a definitive conclusion on the real impact of the metabolic syndrome on knee OA initiation and progression. Recent experimental in vitro and animal studies have helped to begin deciphering the potential roles of each of these factors in the initiation and progression of OA.
Perspectives on the role of metabolic inflammation in OA from obese animal models Beginning in the 1940s, Drs. Martin and Ruth Silberberg studied the role of increased dietary fat on the development of OA in mice. They showed that supplementing rodent chow with lard (30% by weight) increased the incidence of knee OA in C57BL mice by 2-fold (29) . Recent studies replicated these early observations in models of both spontaneous and posttraumatic OA (Table 2) , focusing primarily on changes in inflammatory cytokines and adipokines as mediators of the increase in OA pathology (30) (31) (32) (33) (34) . In spontaneous models, knee OA severity was positively correlated with total body fat, and levels of numerous cytokines and adipokines were also elevated with the percentage of body fat (30) (31) (32) . Statistically adjusting for adiposity using multivariable modeling negated the associations between knee OA and most systemic inflammatory mediators, except for leptin and adiponectin (30, 31) .
These findings are notable since both leptin and adiponectin are implicated in OA pathogenesis (26, 28) . They are also of interest because mice with loss-offunction mutations in the leptin gene or the leptin receptor gene are protected against developing knee OA despite an extreme obesity phenotype, with body weights in excess of 80 gm and body fat levels of .50% (35) . Mice with impaired leptin signaling become obese primarily by hyperphagia, and in the study by Griffin and colleagues (35) , leptin-deficient mice were fed a normal chow-based diet. Increasing body weight by chemically inducing hyperphagia in mice fed a normal chow diet also does not increase knee OA (for review, see ref. 36 ). This finding may be explained by the antiinflammatory and antioxidative actions of aurothioglucose, the chemical agent used to induce hyperphagia. However, it also raises the possibility that an increase in dietary fat or the composition of fat itself contributes to OA pathogenesis.
Mice fed high-fat lard diets supplemented with polyunsaturated fatty acids (PUFAs) or diets composed of vegetable oils (e.g., cottonseed oil) develop less severe knee OA (36) . Fatty acids are well known to modulate inflammation positively or negatively, and recent studies have tested the effect of different types of dietary fatty acids on inflammation in rodent models of idiopathic and posttraumatic OA. Two central classes of lipid mediators of inflammation are omega-6 (n-6) and omega-3 (n-3) PUFAs. Omega-6 PUFAs, such as arachidonic acid, are precursors of proinflammatory eicosanoids, including prostaglandins, thromboxanes, and leukotrienes. Conversely, n-3 PUFAs, such as eicosapentaenoic and docosahexaenoic acids, inhibit inflammation and accelerate its resolution. Obesogenic diets of middle-income and high-income countries, commonly referred to as Western diets, contain a high ratio of n-6:n-3 PUFAs.
Two recent studies in mice have shown that decreasing the ratio of n-6:n-3 PUFAs, either by diet or genetically through the introduction of the fat-1 Figure 1 . Cardiometabolic factors and associated mediators of increased osteoarthritis (OA) pathophysiology. The clustering of cardiometabolic conditions that collectively increase the risk of heart disease, diabetes mellitus, and stroke is referred to as the metabolic syndrome. Emerging data indicate that the metabolic syndrome also increases OA risk by impairing the regulation of numerous metabolic and inflammatory pathways, including adipose tissue inflammation, blood glucose and lipid homeostasis, and vascular inflammation. Dysregulation of these signaling pathways impacts multiple articular joint tissues either directly or indirectly through disrupted tissue paracrine signaling and/or biomechanical function. The net result is an increase in synovial and intraarticular fat inflammation, impaired bone remodeling, and the suppression of cartilage anabolic activity in favor of catabolism. HDL 5 high-density lipoprotein; IL-6 5 interleukin-6; LDL 5 low-density lipoprotein; TNF 5 tumor necrosis factor; PAI-1 5 plasminogen activator inhibitor 1; VEGF 5 vascular endothelial growth factor.
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BERENBAUM ET AL transgene that endogenously converts n-6 to n-3 PUFAs, reduces the development of posttraumatic knee OA (37, 38) . This reduction was associated with a decrease in serum levels of proinflammatory cytokines and adipokines (e.g., interleukin-1b [IL-1b], tumor necrosis factor [TNF], leptin, and resistin), joint synovitis, synovial macrophage infiltration, and heterotrophic joint ossification. Intriguingly, wound healing in an ear-punch model was also improved by reducing the ratio of n-6:n-3 PUFAs (38) . In contrast, the development of early-stage idiopathic knee OA in 1 year-old fat-1-transgenic mice was not reduced compared to control littermates despite lower serum IL-6 and TNF levels (39) . These studies suggest that the ratio of n-6:n-3 PUFAs has the greatest impact on OA progression under conditions of more acute activation of cellular and humoral immune responses, such as following tissue damage or joint trauma. It is not yet clear how n-6 and n-3 PUFAs regulate joint inflammation and repair. There is evidence that the ratio of n-6:n-3 PUFAs directly modulates cytokine-induced catabolic responses in joint connective tissues, such as cartilage (40); however, the effect likely involves heterogeneous cell populations involved in the regulation of wound healing and resolution of inflammation. A recent randomized clinical trial of fish oil supplementation in knee OA patients showed improvement in OA-related pain and function at 2 years, albeit without altering cartilage loss (41) , suggesting that n-3 PUFAs may also reduce inflammation by improving physiologic joint use and function.
Another way in which high-fat diets may stimulate joint inflammation and OA is through activation of innate immune pathways. Obesogenic high-fat diets and alcohol consumption impair the gut mucosal barrier, resulting in increased intestinal permeability and elevated circulating levels of lipopolysaccharide (LPS). In addition, longchain saturated fatty acids have been implicated in promoting low-grade inflammation through activation of the Toll-like receptor (TLR) pathway, specifically TLR-4. Mice lacking functional LPS receptor CD14 and TLR-4 are partially protected against high-fat diet-induced inflammation and related metabolic impairments, such as insulin resistance. Two recent animal studies support a model of systemic LPS inflammation in OA (42, 43) . However, this work is at an early stage, and there are many questions about how TLR-4 or LPS may mediate inflammation in OA (44) .
A growing body of work has implicated dyslipidemia in innate immune pathway activation and OA pathophysiology. Activated synovial macrophages are present in OA joints, especially in patients with DM (34) . One potential mediator of macrophage activation is LDL cholesterol. LDL levels are elevated with obesity and when oxidized stimulate the production of proinflammatory mediators, matrix-degrading proteinases, and growth factors involved in OA pathogenesis (45) . Furthermore, obesity and metabolic syndrome also suppress the production of HDL cholesterol, which exerts antiinflammatory effects on macrophages through down-regulation of TLR-induced proinflammatory cytokines. Mouse models of dietary and genetic-induced hypercholesterolemia increase knee OA pathology, even without increasing body weight (46) (47) (48) (49) (50) . Moreover, statin treatment diminished OA severity in these models, supporting a direct role for cholesterol homeostasis in OA pathogenesis (for review, see ref. 45 ). Recent evidence also indicates a role of cholesterol homeostasis in chondrocyte hypertrophy through regulation of hedgehog signaling (51), indicating multiple potential pathways linking dyslipidemia and OA pathophysiology.
Infrapatellar fat pad as a local regulator of knee joint inflammation
Abdominal adipose tissue inflammation is a central feature of dysregulated metabolism that occurs with obesity. This finding has piqued interest in the infrapatellar fat pad as a local paracrine mediator of knee joint inflammation and OA pathogenesis. Indeed, the infrapatellar fat pad is a source of numerous soluble factors, including cytokines (e.g., IL-1, IL-4, IL-5, IL-6, IL-8, IL-13, interferon-g, and TNF), chemokines (e.g., CCL2), adipokines (e.g., leptin, adiponectin, adipsin, resistin, and visfatin/extracellular NAMPT), growth factors (e.g., basic fibroblast growth factor and vascular endothelial growth factor), free fatty acids, and lipid derivatives (e.g., arachidonic acid and prostaglandin E 2 ) (for review, see ref. 6 ). These factors are derived from adipocytes as well as stromal cells, including resident and infiltrating macrophages and T cells present within the infrapatellar fat pad.
The role of infrapatellar fat pad-derived soluble factors in OA initiation and progression is unclear because the majority of studies have evaluated infrapatellar fat pad cell populations and secreted factors in tissue harvested from joints with end-stage OA during joint replacement surgery. At this late stage of disease, the infrapatellar fat pad contains more antiinflammatory alternatively activated macrophages (CD2061 macrophages) than proinflammatory macrophages activated by classic means (CD861 macrophages) and exerts an anticatabolic effect on cartilage in vitro using infrapatellar fat pad-conditioned medium (52). It is not known if these findings are unique to infrapatellar fat pad tissue from end-stage OA joints or if these are general characteristics of infrapatellar fat pad tissue. 14 
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Clinically, alterations in infrapatellar fat pad MRI signal intensity are significantly and positively associated with knee pain in cross-sectional and longitudinal analyses (53, 54) . Peripatellar synovitis scores are positively associated with synovial neovascularization, hyperplasia, and villi (55) , and infrapatellar fat pad-conditioned medium stimulates the expression of proinflammatory mediators and matrix metalloproteinases (MMPs) in autologous fibroblast-like synoviocytes, suggesting a role for the infrapatellar fat pad in synovial inflammation (56) . Surprisingly, though, infrapatellar fat pad size is negatively associated with knee OA prevalence and risk of progression (57) . These findings imply that a larger healthy infrapatellar fat pad protects against OA, possibly by helping to better distribute joint biomechanical stresses (57) . Alternatively, infrapatellar fat pad size could be indirectly associated with knee OA risk.
In a recent analysis of the infrapatellar fat pad in an aging rodent model of adult-onset obesity and knee OA (58), infrapatellar fat pad mass significantly decreased with age despite increasing total body mass. This decrease occurred independent of changes in adipocyte size, suggesting that the reduction in fat pad size with age is due to an imbalance in the rates of adipogenesis and cell death. Although the basal expression of markers for adipogenesis did not change with age, they were significantly reduced with aging following IL-1b stimulation, suggesting that inflammation negatively regulates infrapatellar fat pad adipogenesis and potentially infrapatellar fat pad size. In this model, aging increased the production of TNF and IL-13 and decreased the expression of markers of antiinflammatory macrophages activated by alternative means. Thus, joint inflammation may mediate the negative association between infrapatellar fat pad size and OA risk. Intriguingly, IL-1b inhibited leptin production in an age-dependent manner. This suggests that aging may protect against OA when joint inflammation is elevated (e.g., after injury) by down-regulating infrapatellar fat pad adipogenesis and adipocyte-derived inflammatory mediators such as leptin.
Although clinical evidence that links alterations in infrapatellar fat pad size or quality to OA risk and pain is growing, the mechanistic understanding of these relationships is poor. Additional studies are needed at the early stages of disease to better evaluate the causeand-effect relationship between infrapatellar fat pad inflammation, size, and OA pathogenesis. Testing in multiple preclinical models of OA (e.g., posttraumatic, diet-induced obesity, aging, and genetic) will help to identify shared and unique mediators of infrapatellar fat pad remodeling and inflammation by OA subtype. Furthermore, the infrapatellar fat pad is highly innervated with nociceptive fibers, and little is known about how changes in infrapatellar fat pad remodeling and inflammation regulate OA pain and joint function.
Energy and nutrient sensors, metabolic syndrome, and OA Evolutionarily conserved cellular energy and nutrient sensors, such as AMP-activated protein kinase (AMPK), sirtuins (SIRTs), and mechanistic target of rapamycin (mTOR), determine how cells respond to excess or insufficient nutrients and changes in cellular energy balance. With the development of obesity or metabolic syndrome-conditions of chronic excess nutrients-these sensors become impaired and further contribute to metabolic syndrome, including abdominal adiposity, DM, and dyslipidemia (59) (60) (61) (62) . These changes include a decrease in AMPK and SIRT activities and an increase in mTOR activity. Understanding how obesity and conditions that contribute to metabolic syndrome also lead to aberrant AMPK, SIRT, and mTOR function provides potential clues as to how metabolic derangements increase the risk of OA.
AMPK is a serine/threonine protein kinase that exists as a heterotrimeric complex consisting of a catalytic a-subunit and two regulatory b-and g-subunits (59). Phosphorylation of a conserved threonine residue within the activation loop of the kinase domain (Thr172) is required for the kinase activity of AMPK (59) . AMPK is activated in response to decreases in cellular energy state by stimulating processes that generate ATP (e.g., fatty acid oxidation and glucose transport), and inhibiting others that consume ATP (e.g., fatty acid and protein synthesis) (59) . In this manner, AMPK allows cells to adjust to changes in energy demand. SIRTs, a conserved family composed of 7 members (SIRTs 1-7), possess NAD1-dependent protein deacetylase, deacylase, and ADP ribosyltransferase activities (63) . They guard against cellular metabolic stress by modifying the activity of metabolic enzymes and gene transcription to balance nutrient supply and demand (63) . Mechanistic target of rapamycin is a serine/threonine kinase that serves as a converging point for signals controlling cellular growth, energy metabolism, nutrient availability, and stress. The mTOR signaling pathway is frequently activated in various tissues under conditions of excessive nutrient intake (63) . Chronic activation of mTOR signaling can lead to the development of insulin resistance (63). These energy and nutrient sensors become dysfunctional when cells are exposed to obesity-associated metabolic derangements, such as high concentrations of blood glucose and fatty acids (e.g., palmitate), low-grade metabolic inflammatory mediators (e.g., TNF), and low concentrations of adiponectin (60, 64) .
Recent studies have implicated dysfunctional AMPK, SIRT, and mTOR activity in OA development and progression. Phosphorylation of AMPKa Thr172 is decreased in human knee OA chondrocytes and cartilage (65) and in mouse knee OA cartilage, compared with their respective normal counterparts (66) . In addition, mouse knee cartilage exhibits an aging-associated reduction in phosphorylation of AMPKa (66) . Moreover, in vitro studies demonstrate that the inflammatory cytokines IL-1b and TNF, as well as biomechanical injury, can cause dephosphorylation of AMPKa in normal articular chondrocytes. This is correlated with increased catabolic responses (e.g., increased MMP-3 and MMP-13 release). All of these effects can be inhibited by AMPK pharmacologic activators (65, 66) . Furthermore, recent in vivo studies show that activation of AMPK by berberine, a natural plant product that is known to activate AMPK, limits both surgically induced knee instability and aging-related OA in mice (67) . Taken together, these findings indicate that sustained AMPK activity in articular chondrocytes appears to be chondroprotective.
Three members of the SIRT family (SIRT-1, SIRT-3, and SIRT-6) have been studied in articular chondrocytes. Among them, SIRT-1 is best characterized so far. Similar to AMPKa phosphorylation, SIRT-1 expression is decreased in both human and mouse knee OA cartilage and in aged mouse knee cartilage (68) (69) (70) . Consequently, adult heterozygous Sirt1 mice and mice with a Sirt1 point mutation lacking SIRT-1 enzyme activity exhibit increased OA progression (71, 72) . Moreover, cartilage-specific Sirt1-knockout mice develop accelerated OA progression (70) . Sustained SIRT-1 expression and activity in articular chondrocytes also appears to be important for cartilage homeostasis. Indeed, SIRT-1 promotes cartilage-specific gene expression (73) , and activation of SIRT-1 in a mouse OA model using an intraarticular injection of resveratrol significantly reduced cartilage destruction (74) . Cartilage SIRT-3 expression was also recently shown to decrease with age, and SIRT-3 deficiency increases acetylation of the antioxidant enzyme SOD2, resulting in impaired SOD2 activity in chondrocytes (75) . In addition, whole-body deletion of SIRT-3 accelerates the development of knee OA (75) . Expression of SIRT-6 is significantly decreased in human OA chondrocytes as well (76) . Depletion of SIRT-6 in human chondrocytes causes increased DNA damage, telomere dysfunction, and premature senescence, which are processes implicated in cartilage degeneration in OA (77) .
Activation of AMPK stimulates the expression and activity of SIRT-1 in articular chondrocytes (78) . Activated AMPK/SIRT-1 signaling increases cellular stress resistance through the downstream targets peroxisome proliferator-activated receptor g coactivator 1a (a master regulator of mitochondrial biogenesis and function) and FoxO3A (a transcription factor that regulates oxidative stress response). In this context, mitochondrial function is preserved, and excessive oxidative stress and inflammation-mediated matrix catabolism are inhibited (79, 80) . Activated AMPK also protects housekeeping cellular quality control in articular chondrocytes by limiting endoplasmic reticulum stress (81) and maintains autophagy capacity (82) . Activation of AMPK can promote SIRT-3 expression in articular chondrocytes as well (LiuBryan R, et al: unpublished observations). Age-related loss of SIRT-3 expression in cartilage may be a consequence of loss of AMPK activity. Loss of mitochondrial function is a hallmark of aging and age-related diseases, which is associated with reduced activity of AMPK and SIRTs (60, 63) . Since loss of SIRT-3 activity results in profound aberrations in mitochondrial function (63) , AMPK/SIRT-3 signaling could play an important role in maintaining normal mitochondrial function in chondrocytes.
Mechanistic target of rapamycin is a potent inhibitor of autophagy, which is a cellular degradative process that maintains fundamental biologic activities during cellular stresses, especially nutrient starvation (60) . Activation of AMPK and SIRT-1 promotes autophagy by inhibiting the activity of mTOR complex (e.g., mTORC1) and enhancing the later steps in autophagosome formation through deacetylation of several autophagy-related proteins, respectively (60) . Chondrocyte autophagy is reduced, with a linked increase in apoptosis, in human knee OA, mouse knee OA, and aged mouse knee cartilage (83) . In mice, cartilage-specific genetic deletion of mTOR (84) and pharmacologic inhibition of mTOR signaling by rapamycin (85) up-regulate autophagy, which reduces the severity of posttraumatic OA.
Cellular energy and nutrient sensors, in particular AMPK and SIRTs, are potential mediators of the systemic (plasma) and local (synovial fluid) effects of adipokines on cartilage degeneration, osteophyte formation, and synovial inflammation (86, 87) . AMPK and SIRTs regulate inflammatory responses, cartilage homeostasis, and bone metabolism (for review, see ref. 88 ). Since dysregulation of AMPK and SIRTs is seen in experimental animal models of obesity and metabolic syndrome, AMPK and SIRTs could be critical mediators in the cross-talk between dysregulated metabolic tissues, such as adipose tissue and joint tissues. 16 BERENBAUM ET AL A recent study showed significantly increased expression of messenger RNA (mRNA) for inflammatory cytokines and adipokines, including TNF, IL-6, and leptin, in the infrapatellar fat pad of SIRT-6 haploinsufficient (SIRT-6 1/2 ) mice compared to wild-type mice (89) . Following consumption of a high-fat diet, expression levels of mRNA for all of these cytokines were enhanced in wildtype and SIRT-6 1/2 mice, with IL-6 mRNA expression further enhanced in SIRT-6 1/2 mice (89). Moreover, SIRT-6 1/2 mice exhibited accelerated cartilage degradation when fed a normal diet, and they displayed greater osteophyte formation and synovial inflammation when fed a high-fat diet (89) . These results suggest that impaired SIRT-6 links metabolic dysfunction with multiple aspects of OA, including cartilage degradation, synovial inflammation, and bone remodeling. Further study is warranted to investigate how energy sensors in joint tissues become dysregulated in response to abnormal systemic and/or local metabolism associated with metabolic syndrome.
AMPK, SIRTs, and mTOR as therapeutic targets for OA
The pathways of AMPK, SIRTs, and mTOR are tightly crosslinked and share many downstream targets that regulate cell processes involved in aging, including mitochondrial biogenesis, cellular metabolism, autophagy, and DNA repair (59) . Increasing evidence indicates that aging, joint injury, low-grade inflammation, and possibly nutritional overload, obesity, and metabolic syndrome impair normal function of energy and nutrient sensors in articular cartilage. Reduced activities of AMPK and SIRTs and increased mTOR activity in articular chondrocytes trigger significant metabolic stress, manifested as mitochondrial dysfunction, oxidative Figure 2 . AMP-activated protein kinase (AMPK) and sirtuins (SIRTs) as potential therapeutic targets for osteoarthritis (OA). Aging, joint injury, low-grade inflammation, and possibly altered metabolism resulting from nutritional overload, obesity, or metabolic syndrome (MetS) impair the activities of the energy sensors AMPK and SIRTs in articular cartilage. In turn, the dysregulated signaling of AMPK and/or SIRTs triggers significant chondrocyte stress by inducing mitochondrial dysfunction, oxidative stress, and inflammation and by weakening cellular quality control, which compromises cell survival and cartilage tissue integrity, ultimately leading to OA development and progression. However, targeted activation of AMPK and SIRTs potentially by dietary restriction, natural plant products used as dietary supplements (e.g., berberine and resveratrol), and drugs already in the clinic (e.g., metformin for type 2 diabetes mellitus and methotrexate for rheumatoid arthritis) could be an attractive therapeutic strategy for OA, particularly for those OA patients who also have metabolic syndrome. Asterisks indicate predicted pathways, arrows indicate activation, and horizontal lines indicate inhibition. stress, and inflammation. As a result, cell survival and tissue integrity and function are compromised, ultimately leading to OA development and progression (Figure 2) . Interestingly, activation of AMPK and SIRTs and inhibition of mTOR signaling are implicated in the beneficial effects of dietary restriction (90) . In addition, some drugs already in the clinic (e.g., metformin for type 2 DM and methotrexate for rheumatoid arthritis), and some natural plant products used as dietary supplements (e.g., berberine and resveratrol) activate the AMPK/SIRT-1 and/or AMPK/mTOR signaling pathways. As such, AMPK, SIRTs, and mTOR are potentially attractive and achievable therapeutic targets for OA. A systemic treatment (e.g., activation of AMPK) may be an effective means to combat both metabolic diseases and OA.
Conclusions
Exciting new discoveries are revealing a vast network of interconnected pathways that regulate metabolism and inflammation. These pathways exist at the molecular level in the form of cellular energy sensors (e.g., AMPK, SIRTs, and mTOR) that regulate enzyme activity, gene transcription, and proteostasis to coordinate cell survival mechanisms. They also exist at the cellular level, where changes in energy metabolism and nutrient utilization impact the activation and resolution of inflammation via effects on both immune and nonimmune cells. At the level of the organism, excess caloric intake, increased saturated and n-6 dietary fat, and insufficient metabolic energy expenditure can impair organ and tissue function, resulting in systems-level dysfunction (e.g., DM) and pathologic paracrine or endocrine proinflammatory signaling (e.g., intestinal or adipose tissue-derived inflammatory mediators). The increasingly recognized role of inflammation in OA, together with the high comorbidity of obesity and OA, set an exciting new path for trying to understand how disrupted metabolic signaling in distant organs or in local articular tissues contributes to an increase in OA risk.
Current prospective epidemiologic studies show clear associations between OA, the metabolic syndrome, and its components, even when controlling for obesity in some studies. Animal models that recapitulate some aspects of the metabolic syndrome also support a role for disrupted metabolic and inflammatory signaling in OA risk independent of obesity itself. Many questions remain, however, about the nature of these interactions. Despite a growing body of clinical evidence of sex-specific associations between components of the metabolic syndrome and OA, few animal studies have tested sex-dependent outcomes in obese OA models. Additional questions remain about the relative role of systemic versus local factors in regulating articular joint tissue inflammation and metabolism. Therefore, we propose the following research agenda to address these questions and additional unmet needs to better understand how metabolic dysfunction mediates joint inflammation and the pathophysiology of OA:
To design an epidemiologic prospective study looking at the risk of hand OA in the presence of metabolic syndrome To design an epidemiologic prospective study looking at the risk of knee/hip/hand OA in the presence of hypertension To design studies and develop model systems evaluating sex-dependent differences in OA risk in the presence of metabolic syndrome and its underlying components To design studies and develop model systems that isolate the effects of body weight, metabolic syndrome components, and aging on tissue-specific cellular and molecular mediators of articular joint inflammation and metabolism To develop methods and model systems to evaluate in vivo cellular energy metabolism and metabolic signaling networks within and between articular joint tissues under physiologic and pathophysiologic conditions To design clinical and preclinical studies that test the efficacy of metabolic-based therapies (e.g., dietary, natural products, and pharmaceutical therapies) on OA risk in the presence of obesity and metabolic syndrome
